Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Tomer Izraeli
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- -1.46
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 15.84
Financials
Net Income
$-3.16MEBITDA
$-3.61MFree Cash Flow
$-2.71MEPS (diluted)
$-1.96Shares Outstanding (diluted)
1.61M-61.7%Operating Expenses
$3.61MCash & Debt
$12.27MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-3.33M | $-2.07 |
| 2024 | $0.00 | $-1.54M | $-134.14 |
| 2023 | $0.00 | $-600.0K | $0.00 |
| 2022 | $0.00 | $-779.0K | $0.00 |
| 2021 | $0.00 | $-711.0K | $0.00 |
| 2020 | $0.00 | $-73.0K | $0.00 |
Valuation
PLRZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
…five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).
View source ↗
Insider trading
Open-market buys and sells by PLRZ officers and directors.
- Bought
- —
- Sold
- $133k
0 trades
6 trades
- Izraeli Tomersold
- Carmel Lironsold
- Adler Ozsold
- Carmel Lironsold
- Izraeli Tomersold
- Turgeman Tidharsold
19 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.